Detection is the Key to Success
About MycoMed Technologies
MycoMed is focused on development and commercialization of products to enable early detection and prevention of fungal infections.
Much progress in medicine is accompanied by risks for infections, caused by weakening of natural defenses in the immune system. People who receive organ transplantation, cancer therapy and medications to suppress the immune system have risks for infections caused by fungi. These organisms are everywhere in our environment and infections are difficult to treat. Prevention is a key step to improving outcomes. Our first product, a urine test to detect fungal infections in the lung, is in clinical studies now.
Mycomed Technologies is located in the Johns Hopkins Fast Forward Accelerator in Baltimore, Maryland. This organization has been operating since 2014. MycoMed is a U.S. Small Business Administration-certified Women Owned Small Business (WOSB).